应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
未开盘 07-02 16:08:20
1.990
+0.080
+4.19%
最高
2.070
最低
1.910
成交量
51.05万
今开
1.910
昨收
1.910
日振幅
8.38%
总市值
9.93亿
流通市值
9.93亿
总股本
4.99亿
成交额
101.72万
换手率
0.10%
流通股本
4.99亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
美股异动 | 医药板块再获资金切换 葛兰素史克(GSK.US)涨近5%
智通财经 · 07-02 23:41
美股异动 | 医药板块再获资金切换 葛兰素史克(GSK.US)涨近5%
星昊医药（920017）披露完成工商变更登记及公司章程备案并取得营业执照的公告，7月2日股价下跌1.5%
证券之星 · 07-02 22:54
星昊医药（920017）披露完成工商变更登记及公司章程备案并取得营业执照的公告，7月2日股价下跌1.5%
医药大时代重启：全产业链核心龙头投资逻辑深度拆解
独角兽智库 · 07-02 20:37
医药大时代重启：全产业链核心龙头投资逻辑深度拆解
开拓药业-B6月无新增发行或股份变动
公告速递 · 07-02 17:05
开拓药业-B6月无新增发行或股份变动
7月2日健民集团涨7.67%，银河医药混合A基金重仓该股
证券之星 · 07-02 16:27
7月2日健民集团涨7.67%，银河医药混合A基金重仓该股
【券商聚焦】申万宏源首予劲方医药-B(02595)“买入”评级 指其RAS疗法具全球领先优势
金吾财讯 · 07-02 14:51
【券商聚焦】申万宏源首予劲方医药-B(02595)“买入”评级 指其RAS疗法具全球领先优势
港股午评：恒指、恒科齐涨，生物科技指数大涨近5%；黄金、医药板块冲高，半导体大跌；华虹宏力、中芯国际、智谱、MiniMax集体飘绿
中新经纬 · 07-02 12:03
港股午评：恒指、恒科齐涨，生物科技指数大涨近5%；黄金、医药板块冲高，半导体大跌；华虹宏力、中芯国际、智谱、MiniMax集体飘绿
超4000股上涨 科技行情终结？机构：勿做极端切换
国际金融报 · 07-01 23:26
超4000股上涨 科技行情终结？机构：勿做极端切换
北京中医药代表团访俄开展传统医药交流合作
中国新闻网 · 07-01 16:57
北京中医药代表团访俄开展传统医药交流合作
7月1日药康生物涨6.49%，天弘医药创新A基金重仓该股
证券之星 · 07-01 16:38
7月1日药康生物涨6.49%，天弘医药创新A基金重仓该股
百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代
华夏时报网 · 07-01 13:52
百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代
亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%
证券之星 · 07-01 08:03
亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%
华泰 | 策略：当前各类资金消费仓位几何？
华泰睿思 · 07-01 07:26
华泰 | 策略：当前各类资金消费仓位几何？
创胜集团医药-B(06628)授出45.15万股奖励股份及2.25万份购股权
智通财经 · 06-30 23:14
创胜集团医药-B(06628)授出45.15万股奖励股份及2.25万份购股权
创胜集团医药-B(06628.HK)：徐汉森获选举为公司非执行董事
智通财经 · 06-30 20:40
创胜集团医药-B(06628.HK)：徐汉森获选举为公司非执行董事
ST金花：聚焦制药主业，以医药大健康领域为核心，适度多元化发展
证券之星 · 06-30 16:03
ST金花：聚焦制药主业，以医药大健康领域为核心，适度多元化发展
新股消息 | 国内儿科医药营销龙头科郦二次递表港交所 妈咪爱、易坦静为支柱产品
智通财经 · 06-30 14:21
新股消息 | 国内儿科医药营销龙头科郦二次递表港交所 妈咪爱、易坦静为支柱产品
跟风不怕跌
丫丫港股圈 · 06-29
跟风不怕跌
6月29日百普赛斯涨9.22%，圆信永丰医药健康A基金重仓该股
证券之星 · 06-29
6月29日百普赛斯涨9.22%，圆信永丰医药健康A基金重仓该股
6月29日悦康药业涨5.17%，富国医药创新股票A基金重仓该股
证券之星 · 06-29
6月29日悦康药业涨5.17%，富国医药创新股票A基金重仓该股
加载更多
公司概况
公司名称：
开拓药业-B
所属市场：
SEHK
上市日期：
--
主营业务：
开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。
发行价格：
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.99,"timestamp":1782979700278,"preClose":1.91,"halted":0,"volume":510500,"delay":0,"changeRate":0.04188481675392674,"floatShares":499000000,"shares":499000000,"eps":-0.5140224899258853,"marketStatus":"未开盘","change":0.08,"latestTime":"07-02 16:08:20","open":1.91,"high":2.07,"low":1.91,"amount":1017155,"amplitude":0.08377,"askPrice":1.99,"askSize":500,"bidPrice":1.95,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.5129757421277596,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.91,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":0.3779801569420863,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2648703689","title":"美股异动 | 医药板块再获资金切换 葛兰素史克(GSK.US)涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648703689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648703689?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:41","pubTimestamp":1783006872,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，医药板块再获资金切换，葛兰素史克(GSK.US)涨近5%，诺和诺德(NVO.US)、赛诺菲安万特(SNY.US)涨超3%，礼来(LLY.US)涨超2%。分析指出，近期科技股、AI大模型及半导体板块持续调整，以及市场对AI算力投资过热、成本控制及高估值产生严重担忧，相关板块出现高位震荡与获利回吐，资金集中向具有强刚需、受经济周期冲击小的医药板块切换。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","GSK.UK","BK4532","BK4588","GSKH","09939","BK4007","BK1515","BK1161","BK4585","GSK","BK1574","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648468610","title":"星昊医药（920017）披露完成工商变更登记及公司章程备案并取得营业执照的公告，7月2日股价下跌1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648468610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648468610?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:54","pubTimestamp":1783004055,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，星昊医药报收于17.11元，较前一交易日下跌1.5%，最新总市值为21.2亿元。近日，星昊医药发布《关于完成工商变更登记及公司章程备案并取得营业执照的公告》。公告显示，公司于2026年4月23日召开第七届董事会第八次会议，2026年5月15日召开2025年年度股东会，审议通过《关于减少公司注册资本及修订<公司章程>并办理工商登记的议案》。除注册资本变更外，其他登记事项未发生变化。修订后的《公司章程》已备案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648688852","title":"医药大时代重启：全产业链核心龙头投资逻辑深度拆解","url":"https://stock-news.laohu8.com/highlight/detail?id=2648688852","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648688852?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:37","pubTimestamp":1782995820,"startTime":"0","endTime":"0","summary":"药明康德是全球 CXO 行业的全产业链龙头，覆盖从早期药物发现到商业化生产的全流程服务，客户矩阵囊括全球 Top 级药企，技术平台与产能布局均处于全球第一梯队。公司依托国内工程师红利持续巩固成本优势，随着全球创新研发需求复苏，订单与业绩增速将逐步回升，是 CXO 赛道最具确定性的核心资产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmmmu2678975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159938","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160328961","title":"开拓药业-B6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1160328961","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160328961?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:05","pubTimestamp":1782983159,"startTime":"0","endTime":"0","summary":"开拓药业有限公司（09939）于2026年7月2日披露了截至2026年6月30日的证券变动月报表。报告显示，公司本月无新增发行或股份变动。\n根据公告，截至当月末，公司法定股本为700,000,000股普通股，面值均为0.0001美元，注册股本总额维持在美元70,000；已发行股份数由上月底的498,660,100股保持不变，且无库藏股，公司已满足相关公众持股量要求。报告期内，未发生任何股份发行、购回、注销或库藏股增减事宜，也无新增股份期权或其他股权激励项目的变动。\n公司同时确认已遵守香港联合交易所有限公司《上市规则》及相关法律法规的要求。公告由公司董事会主席、执行董事及行政总裁童友之签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648508809","title":"7月2日健民集团涨7.67%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648508809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648508809?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:27","pubTimestamp":1782980850,"startTime":"0","endTime":"0","summary":"证券之星消息，7月2日健民集团涨7.67%，收盘报28.2元，换手率4.72%，成交量7.23万手，成交额2.02亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河医药混合A。方伟在任的基金产品包括:银河康乐股票A，管理时间为2021年5月10日至今，期间收益率为-33.34%；银河医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200026924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0250","BK1574","BK0209","BK1161","BK0188","159938","600976"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648572826","title":"【券商聚焦】申万宏源首予劲方医药-B(02595)“买入”评级 指其RAS疗法具全球领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2648572826","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648572826?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:51","pubTimestamp":1782975101,"startTime":"0","endTime":"0","summary":"报告首次覆盖给予“买入”评级，目标价34.81港元。研报核心逻辑围绕公司核心管线GFH375的全球领先地位展开。GFH375是一款靶向KRAS G12D高频突变的口服抑制剂，该突变在胰腺癌中突变率约40%，且与不良预后密切相关。公司核心产品GFH375预计于2028年上市并开始贡献产品销售收入。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984986","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000166","09939","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648576095","title":"港股午评：恒指、恒科齐涨，生物科技指数大涨近5%；黄金、医药板块冲高，半导体大跌；华虹宏力、中芯国际、智谱、MiniMax集体飘绿","url":"https://stock-news.laohu8.com/highlight/detail?id=2648576095","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648576095?lang=zh_cn&edition=full","pubTime":"2026-07-02 12:03","pubTimestamp":1782964980,"startTime":"0","endTime":"0","summary":"2日，港股主要指数全线上涨，恒生生物科技指数盘中涨超6%。截至午间收盘，恒指涨1.19%，恒生科技指数涨0.62%，恒生生物科技指数涨4.87%。盘面上，造纸、汽车、黄金、家电、医药生物、非银金融等板块上涨。半导体板块大跌，壁仞科技、天数智芯、兆易创新等跌幅居前；硬件设备、软件、电气设备等板块下跌。科网股方面，小米集团、美团、京东集团、快手、阿里巴巴等上涨，联想集团飘绿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023791665595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TEKX","PICK","PALL","XME","SMH","OUNZ","SOXS","CHPS","USG","JDST","GLTR","GOLY","XSD","SSG","159831","SOXY","DGP","USD","UYM","GLDM","SOXX","SOXL","VGT","SOXQ","01347","GDXD","GOAU","IAU","DUST","07226","GDX","SGOL","DBC","BTGD","CEF","GDXU","CHPY","GDXY","RING","VXUS","AAAU","GLL","BEGS","09939","UGL","688347","DULL","FTXL","BAR","FGDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648254753","title":"超4000股上涨 科技行情终结？机构：勿做极端切换","url":"https://stock-news.laohu8.com/highlight/detail?id=2648254753","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648254753?lang=zh_cn&edition=full","pubTime":"2026-07-01 23:26","pubTimestamp":1782919560,"startTime":"0","endTime":"0","summary":"7月1日，A股超4300只个股上涨，市场风格出现明显切换，赚钱效应向非科技板块集中。受外围科技股回调影响，通信、电子等科技板块盘中大幅调整；市场成交额放量至3.68万亿元，资金明显流向消费、医药、券商等传统领域。受访人士表示，科技股的调整属于交易层面的良性换手，低位板块的上涨更多是超跌修复，而非趋势反转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607013790633936.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607013790633936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","07261","BK4588","VGT","03455","BK1574","07568","03034","09939","09834","399300","TTTN","XLK","BK1161","07522","03086","07266","02834","159982","BK4585","ARTY","09086","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648193675","title":"北京中医药代表团访俄开展传统医药交流合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648193675","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648193675?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:57","pubTimestamp":1782896238,"startTime":"0","endTime":"0","summary":"中新网莫斯科7月1日电应俄罗斯联邦卫生部国家医学研究中心邀请，北京市中医药代表团6月30日至7月1日在俄罗斯首都莫斯科开展传统医药交流访问，落实中俄两国在传统医药领域的合作共识，推动双方在中医药特别是康复医学领域的临床实践、人才培养及科研合作等方面的务实交流。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607013790295077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607013790295077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1574","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515767","title":"7月1日药康生物涨6.49%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515767?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:38","pubTimestamp":1782895086,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日药康生物涨6.49%创60日新高，收盘报25.77元，换手率2.65%，成交量10.88万手，成交额2.68亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为5.71亿元，最新净值0.9745，较上一交易日下跌0.07%，近一年上涨10.94%。天弘医药创新A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","BK0216","159938","688046","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648559726","title":"百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2648559726","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648559726?lang=zh_cn&edition=full","pubTime":"2026-07-01 13:52","pubTimestamp":1782885155,"startTime":"0","endTime":"0","summary":"4.46亿元补税计入2026年损益，刚刚扭亏为盈的百济神州，正在为一场突如其来的补税“埋单”。2026年6月27日，百济神州一纸公告引发关注：公司一家境内全资子公司需补缴税款及滞纳金合计约4.46亿元。而就在不久前，这家创新药龙头刚刚摘掉“未盈利”的标签，首次实现年度盈利，并上调全年业绩指引。但百济神州并非个案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607013790080574.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607013790080574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","BK1583","BK4526","BK1588","LU0307460666.USD","BK1515","BK1574","LU1770034418.SGD","BK0239","BK4139","159938","688235","LU1303224171.USD","BK1500","BK4588","LU0588546209.SGD","BK1161","LU1251922891.USD","LU2328871848.SGD","09939","06160","BK4585","LU1969619763.USD","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648459390","title":"亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648459390","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648459390?lang=zh_cn&edition=full","pubTime":"2026-07-01 08:03","pubTimestamp":1782864190,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，亚虹医药于7月1日将有1.35亿股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本23.68%。最近一年内，该股累计解禁5623.45万股，占总股本的9.83%。本文数据来源于亚虹医药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100009448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0239","159938","BK1161","BK1574","BK1515","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648591450","title":"华泰 | 策略：当前各类资金消费仓位几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2648591450","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648591450?lang=zh_cn&edition=full","pubTime":"2026-07-01 07:26","pubTimestamp":1782861960,"startTime":"0","endTime":"0","summary":"弹性资金的缺席或压制了消费板块向上修复的斜率。基金对消费配置已降至历史低位，向下的空间与动力或相对有限。中长线资金对消费关注明显回升险资、社保是消费的边际买盘。此外，国家队资金消费超配比例虽在抬升，但剔除涨跌幅后实际并未增仓，超配上行或更多是被动提升，不宜将国家队视为消费的增量买盘。近期剔除涨跌幅来看，26Q1险资主要加仓家电、食品饮料、医药等行业，三级行业中，主要加仓消费中的白色家电、白酒等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649856641&idx=5&sn=9a98c7709329e8a7528cb3f371b3e03a&chksm=894bfcae29959a49174b074129b890721e21f88fdb3defa25f9cde9705bd633607303b2813a1&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4588","FDN","BK1574","BK1161","09939","BK4585","BK4550","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647550355","title":"创胜集团医药-B(06628)授出45.15万股奖励股份及2.25万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2647550355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647550355?lang=zh_cn&edition=full","pubTime":"2026-06-30 23:14","pubTimestamp":1782832463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B(06628)发布公告，于2026年6月30日，公司根据股份激励计划向136名奖励承授人授出45.15万股奖励股份及根据股份激励计划向9名购股权承授人授出2.25万份购股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","BK1161","06628","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647755650","title":"创胜集团医药-B(06628.HK)：徐汉森获选举为公司非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2647755650","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647755650?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:40","pubTimestamp":1782823237,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","06628","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647953581","title":"ST金花：聚焦制药主业，以医药大健康领域为核心，适度多元化发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2647953581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647953581?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:03","pubTimestamp":1782806597,"startTime":"0","endTime":"0","summary":"证券之星消息，ST金花(600080)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，公司核心产品精准对应“银发经济”下庞大的老年骨健康与免疫管理需求。请问，公司是否将“银发经济”或“大健康”明确为战略方向？在产品研发与市场推广上，是否有针对性的布局规划？ST金花回复：尊敬的投资者您好！感谢您的关注。公司以“聚焦制药主业，以医药大健康领域为核心，适度多元化发展”为战略目标。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","159938","BK0239","600080","BK1574","BK1191","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647587234","title":"新股消息 | 国内儿科医药营销龙头科郦二次递表港交所 妈咪爱、易坦静为支柱产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2647587234","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647587234?lang=zh_cn&edition=full","pubTime":"2026-06-30 14:21","pubTimestamp":1782800508,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647889055","title":"跟风不怕跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2647889055","media":"丫丫港股圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647889055?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:35","pubTimestamp":1782729317,"startTime":"0","endTime":"0","summary":"炒概念的当然没利空","market":"us","thumbnail":"http://admin.yyhkstock.com/upload/picture/20190731/495e9275597953c436e8fef9b7eff63e.jpg","type":0,"news_type":0,"thumbnails":["http://admin.yyhkstock.com/upload/picture/20190731/495e9275597953c436e8fef9b7eff63e.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://admin.yyhkstock.com/detail?id=5709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","LU2083900584.USD","APLY","LU1366333091.USD","AAPL","AAPD","AAPB","LU2125154778.USD","LU0949170426.SGD","LU0061474960.USD","AAPY","IE000KEQY171.SGD","IE00B1BXHZ80.USD","LU2381873111.SGD","LU0215105999.USD","LU0316494557.USD","BK4576","LU2271345857.HKD","IE0001KFT4U8.USD","LU2462591277.SGD","LU2471134879.HKD","LU1582986433.USD","AAPX","LU2087621335.USD","LU1720051108.HKD","LU1496350171.SGD","LU2347655073.USD","LU1989764664.SGD","09939","AAPW","IE00BQXX3D17.EUR","IE00BN8TJ469.HKD","LU0444973449.USD","LU2750360997.AUD","DRAM","MACW.SI","BK4574","AAPU","LU0719512351.SGD","LU2756315664.SGD","SG9999001424.SGD","LU0203201768.USD","IE00BJJMRY28.SGD","LU1267930490.SGD","LU1868836757.USD","LU1839511570.USD","LU0661504455.SGD","LU0210528500.USD","HK0000320264.USD","LU1582987324.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322190","title":"6月29日百普赛斯涨9.22%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322190?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:53","pubTimestamp":1782723231,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日百普赛斯涨9.22%，收盘报47.75元，换手率8.01%，成交量10.1万手，成交额4.66亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.66亿元，最新净值1.6714，较上一交易日下跌4.03%，近一年下跌3.56%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","301080","150219","09939","BK1574","BK0216","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322503","title":"6月29日悦康药业涨5.17%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322503?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:46","pubTimestamp":1782722800,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日悦康药业涨5.17%创60日新低，收盘报13.01元，换手率3.43%，成交量15.42万手，成交额1.98亿元。重仓悦康药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK1161","BK0239","BK1574","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":-0.2519},{"period":"3month","weight":-0.2462},{"period":"6month","weight":-0.0245},{"period":"1year","weight":0.3724},{"period":"ytd","weight":0.0153}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1146},{"period":"3month","weight":-0.0821},{"period":"6month","weight":-0.1247},{"period":"1year","weight":-0.0482},{"period":"ytd","weight":-0.1005}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.714286,"avgChangeRate":0.119785},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}